Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rho guanine nucleotide exchange factor 35 (ARHGEF35) is a member of the RhoGEF family, proteins that activate Rho family small GTPases by facilitating the exchange of GDP for GTP. These proteins regulate actin cytoskeleton remodeling, cell adhesion, and interactions with the extracellular matrix. Although there is little direct experimental evidence specifically characterizing ARHGEF35, it is assumed to influence actin dynamics and cellular adhesiveness, similar to other RhoGEFs. Dysregulation of this class of proteins is known to contribute to processes such as cell migration and tumor metastasis, but there is no evidence that ARHGEF35 is currently considered a direct therapeutic target or is involved in any specific human disease
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rho guanine nucleotide exchange factor 35 (ARHGEF35).